Sales of drugs to treat or prevent infectious diseases are growing at around 17% year on year in Australia and Russia, at double the rate of the next fastest-growing market, India. All these three fast-growing markets are small, however, adding up to only 3.5% of the global total in 2016, while the growth in the large markets of the USA and China averages out at only 3.3%.
Infectious diseases are disorders caused by pathogenic organisms such as bacteria, viruses, fungi or parasites. These diseases can be transmitted or spread from one person to another through direct or indirect contact or indirect contact. Anti-infective drugs are used to treat or prevent these infectious diseases by inhibiting the spread of an infectious agent (static) or by killing the infectious agent (cidal). The main anti-infective drugs include antibiotics, antifungals, antimalarial agents, antituberculosis agents, antiviral agents, penicillins, sulfonamides and tetracyclines.
In the developed world, the incidence of the major kinds of lethal infectious illness has been subtantially reduced despite periodic viral epidemics such as ‘flu and the recent return of tuberculosis affecting small numbers of patients. That helps explain the low rate of growth of the anti-infective drugs market in the USA. In the less developed world, fatal diseases such as malaria still have high prevalence, while typhoid is a continuing threat in areas with poor water quality and sanitation. This helps account for high market growth rates in India and (Asiatic) Russia. Climatic conditions can encourage fungal and bacterial illness, an effect seen in parts of Australia.
USA pharmaceuticals companies Gilead Sciences and Merck are the market leaders in anti-infective drug sales, followed by the British drug manufacturer GlaxoSmithKline. Just under 60% of the global total is split among small producers outside the top ten in the market. Generic versions of out-of-patent drugs are significant.
One of the trends shaping the market is innovations of new drugs. Companies in the anti-infective drugs market are working towards constant innovation to provide more effective drugs and also to sustain in the competition of the market. The FDA approved 22 new drugs in 2016. Among them, drugs for infectious diseases held the largest share with 40% (9) approvals. Recently approved antibiotic drugs include Descovy from Gilead Lifesciences, Zepatier from Merck & Co. and others.
Where to Learn More
Read Anti-Infective Drugs Global Market Report 2018 from The Business Research Company for information on the following:
Markets Covered: Antibiotics, Antivirals, Antifungals, Others (Antihelmethic, Antiprotozoal)
Companies Mentioned: Pfizer Inc., GlaxosmithKline, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, and Sanofi
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293 Email: [email protected]
Anti-Infective Drugs Market By Country